专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09028801B2 Diagnosis of neurodegenerative diseases 有权
标题翻译：诊断神经退行性疾病
公开(公告)号：US09028801B2
公开(公告)日：2015-05-12
申请号：US11792686
申请日：2005-12-07
申请人： Malcolm Andrew Ward , John Collinge , Graham Stuart Jackson , Emma McGregor , Nicola Louise Leeds , James Campbell , Jules Arthur Westbrook , Helen Louise Byers
发明人： Malcolm Andrew Ward , John Collinge , Graham Stuart Jackson , Emma McGregor , Nicola Louise Leeds , James Campbell , Jules Arthur Westbrook , Helen Louise Byers
IPC分类号： A61B5/145 , G01N33/48 , C07K14/805 , C07K14/75 , C07K14/705 , G01N33/68
CPC分类号： G01N33/6896 , G01N2800/2828 , G01N2800/56 , G01N2800/60
摘要： The invention relates to a method of diagnosis of vCJD in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being: beta-actin (SwissProt Acc. No. P60709), apolipoprotein A-IV precursor (SwissProt Acc. No. P06727); haptoglobin beta-chain consisting of residues 162-406 (SwissProt Acc. No. P00738); haemoglobin beta chain (SwissProt Acc. No. P02023); or alpha-1-antitrypsin (SwissProt Acc. No. P01009); or a decreased concentration of a protein in the diagnostic sample, compared with a sample of a control, normal human subject, the protein being plasma protease (C1) inhibitor precursor (SwissProt Acc. No. P05155); complement component 1, s sub-component (SwissProt Acc. No. P09871); butyrylcholinesterase precursor (SwissProt Acc. No. P06276); complement component C4B (SwissProt Acc. No. P01028); lumican (SwissProt Acc. No. P51884); alpha-fibrinogen precursor (SwissProt Acc. No. P02671); IGHG4 protein (Swiss Prot Acc. No. Q8TC63) or immunoglobulin lambda heavy chain. Other marker proteins are also disclosed.
摘要翻译：本发明涉及一种诊断样品中vCJD的方法，该方法是从人体受试者获取的有效身体组织的诊断样本中，其与检测样本中的蛋白质的浓度相比较，与对照人受试者相比，蛋白质是：β-肌动蛋白（SwissProt Acc.P60709），载脂蛋白A-IV前体（SwissProt Acc.Po6727）; 由残基162-406组成的触珠蛋白β链（SwissProt Acc.P00738）; 血红蛋白β链（SwissProt Acc。编号P02023）; 或α-1-抗胰蛋白酶（SwissProt Acc。编号P01009）; 或与对照组，正常人受试者的样品，蛋白质是血浆蛋白酶（C1）抑制剂前体（SwissProt Acc.No.P05155））相比，诊断样品中蛋白质的浓度降低。补充成分1的子成分（SwissProt Acc。No.P09871）; 丁酰胆碱酯酶前体（SwissProt Acc.Po6276）; 补体成分C4B（SwissProt Acc。No.P01028）; lumican（SwissProt Acc。No. P51884）; α-纤维蛋白原前体（SwissProt Acc。编号P02671）; IGHG4蛋白（Swiss Prot Acc。No.Q8TC63）或免疫球蛋白λ重链。还公开了其它标记蛋白。

2. 发明申请

US20080213802A1 Diagnosis of Neurodegenerative Diseases 有权
标题翻译：诊断神经退行性疾病
公开(公告)号：US20080213802A1
公开(公告)日：2008-09-04
申请号：US11792686
申请日：2005-12-07
申请人： Malcolm Andrew Ward , John Collinge , Graham Stuart Jackson , Emma McGregor , Nicola Louise Leeds , James Campbell , Jules Arthur Westbrook , Helen Louise Byers
发明人： Malcolm Andrew Ward , John Collinge , Graham Stuart Jackson , Emma McGregor , Nicola Louise Leeds , James Campbell , Jules Arthur Westbrook , Helen Louise Byers
IPC分类号： G01N33/53 , C12Q1/02 , C12Q1/46
CPC分类号： G01N33/6896 , G01N2800/2828 , G01N2800/56 , G01N2800/60
摘要： The invention relates to a method of diagnosis of vCJD in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being: beta-actin (SwissProt Ace. No. P60709), apolipoprotein A-IV precursor (SwissProt Acc. No. P06727); haptoglobin beta-chain consisting of residues 162-406 (SwissProt Acc. No. P00738); haemoglobin beta chain (SwissProt Ace. No. P02023); or alpha-1-antitrypsin (SwissProt Ace. No. P01009); or a decreased concentration of a protein in the diagnostic sample, compared with a sample of a control, normal human subject, the protein being plasma protease (C1) inhibitor precursor (SwissProt Acc. No. P05155); complement component 1, s sub-component (SwissProt Acc. No. P09871); butyrylcholinesterase precursor (SwissProt Acc. No. P06276); complement component C4B (SwissProt Acc. No. P01028); lumican (SwissProt Ace. No. P51884); alpha-fibrinogen precursor (SwissProt Ace. No. P02671); IGHG4 protein (Swiss Prot Ace. No. Q8TC63) or immunoglobulin lambda heavy chain. Other marker proteins are also disclosed.
摘要翻译：本发明涉及一种诊断样品中vCJD的方法，该方法是从人体受试者获取的有效身体组织的诊断样本中，其与检测样本中的蛋白质的浓度相比较，与对照人受试者相比，蛋白质是：β-肌动蛋白（SwissProt Ace.No.P60709），载脂蛋白A-IV前体（SwissProt Acc.Po6727）; 由残基162-406组成的触珠蛋白β链（SwissProt Acc.P00738）; 血红蛋白β链（SwissProt Ace。编号P02023）; 或α-1-抗胰蛋白酶（SwissProt Ace.Po1009）; 或与对照组，正常人受试者的样品，蛋白质是血浆蛋白酶（C1）抑制剂前体（SwissProt Acc.No.P05155））相比，诊断样品中蛋白质的浓度降低。补充成分1的子成分（SwissProt Acc。No.P09871）; 丁酰胆碱酯酶前体（SwissProt Acc.Po6276）; 补体成分C4B（SwissProt Acc。No.P01028）; lumican（SwissProt Ace。No. P51884）; α-纤维蛋白原前体（SwissProt Ace。编号P02671）; IGHG4蛋白（Swiss Prot Ace。No.Q8TC63）或免疫球蛋白λ重链。还公开了其它标记蛋白。

3. 发明授权

US08506957B2 Methods and compositions for monitoring progression of huntington's disease 失效
标题翻译：监测亨廷顿病进展的方法和组成
公开(公告)号：US08506957B2
公开(公告)日：2013-08-13
申请号：US11792758
申请日：2005-12-07
申请人： Nicola Louise Leeds , Malcolm Andrew Ward , Sarah Joanna Tabrizi , Annette Dalrymple , Emma McGregor , James Campbell , Jules Arthur Westbrook , Helen Louise Byers
发明人： Nicola Louise Leeds , Malcolm Andrew Ward , Sarah Joanna Tabrizi , Annette Dalrymple , Emma McGregor , James Campbell , Jules Arthur Westbrook , Helen Louise Byers
IPC分类号： A61K39/395 , G01N33/68
CPC分类号： G01N33/6896 , G01N2800/2828 , G01N2800/56 , G01N2800/60
摘要： The invention relates to a method of diagnosis of Huntington's Disease in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an altered concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being selected from: Swiss Prot accession number: Protein name; P10909: Clusterin precursor; P00738: Haptoglobin precursor; P01009: Alpha-1-antitrypsin precursor; P01024: Complement C3 precursor; P01620: 1g kappa chain V-III region; P01834: 1 g kappa chain C region P01842: 1g lambda chain C regions; P01857: 1g gamma-1 chain C region; P01859: Ig gamma-2 chain C region; P01876: 1g alpha-1 chain C region P02647: Apolipoprotein A-I precursor; P02649: Apolipoprotein E precursor; P02652: Apolipoprotein A-II precursor; P02655: Apolipoprotein C-II precursor; P02656: Apolipoprotein C-II precursor P02671: Fibrinogen alpha/alpha-E chain precursor; P02763: Alpha-1-acid glycoprotein 1 precursor; P02766: Transthyretin precursor; P02768: Serum albumin precursor; P02787: Serotransferrin precursor; P04196: Histidine-rich glycoprotein precursor; P06727: Apolipoprotein A-IV precursor; P19652: Alpha-1-acid glycoprotein 2 precursor; P68871/P02042: Hemoglobin beta chain/Hemoglobin delta chain; P60709: Beta actin.
摘要翻译：本发明涉及一种在人受试者的有效身体组织的诊断样本中诊断亨廷顿病的方法，其包括检测诊断样品中蛋白质的浓度变化，与对照人受试者的样品相比，该蛋白质选自：瑞士抗原登录号：蛋白质名称; P10909：Clusterin前体; P00738：近红球蛋白前体; P01009：α-1-抗胰蛋白酶前体; P01024：补体C3前体; P01620：1gκ链V-III区; P01834：1g卡巴链C区P01842：1gλ链C区; P01857：1gγ-1链C区; P01859：Igγ-2链C区; P01876：1gα-1链C区P02647：载脂蛋白A-1前体; P02649：载脂蛋白E前体; P02652：载脂蛋白A-II前体; P02655：载脂蛋白C-II前体; P02656：载脂蛋白C-II前体P02671：纤维蛋白原α/α-E链前体; P02763：α-1-酸性糖蛋白1前体; P02766：曲氨酸蛋白前体; P02768：血清白蛋白前体; P02787：血清转铁蛋白前体; P04196：富含组氨酸糖蛋白前体; P06727：载脂蛋白A-IV前体; P19652：α-1酸性糖蛋白2前体; P68871 / P02042：血红蛋白β链/血红蛋白三角链; P60709：β肌动蛋白

4. 发明申请

US20120071337A1 METHODS 审中-公开
标题翻译：方法
公开(公告)号：US20120071337A1
公开(公告)日：2012-03-22
申请号：US13146121
申请日：2010-01-26
申请人： Simon Harold Lovestone , Andreas Christian Güntert , James Campbell , Helen Louise Byers , Darragh P.W. O'Brien
发明人： Simon Harold Lovestone , Andreas Christian Güntert , James Campbell , Helen Louise Byers , Darragh P.W. O'Brien
IPC分类号： C40B30/04 , C07K7/06 , G01N27/00 , C40B40/10 , G01N33/566 , C12Q1/37
CPC分类号： G01N33/6896 , G01N2800/2821
摘要： The invention provides a method for aiding the diagnosis or prognostic monitoring of Alzheimer's disease in a subject, said method comprising; providing a sample of blood obtained from said patient; assaying the amount of gelsolin present in said sample; comparing the amount of gelsolin present in said sample to a reference amount of gelsolin present in a sample from a healthy subject, wherein detection of a gelsolin level in the sample from said patient which is lower than the gelsolin level in the reference sample indicates an increased likelihood of Alzheimer's disease in said patient. Other markers are C1 protease inhibitor and ceruloplasmin. Both blood samples and tissue samples have been investigated.
摘要翻译：本发明提供了一种帮助受试者中阿尔茨海默病的诊断或预后监测的方法，所述方法包括：提供从所述患者获得的血液样品; 测定所述样品中存在的凝溶胶蛋白的量; 将所述样品中存在的凝溶胶蛋白的量与来自健康受试者的样品中存在的参考量的凝溶胶蛋白进行比较，其中来自所述患者的样品中凝血酶蛋白水平的检测低于参考样品中的凝溶胶蛋白水平，表明增加患有阿尔茨海默病的可能性。其他标记物是C1蛋白酶抑制剂和血浆铜蓝蛋白。血液样本和组织样本均已被调查。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式